GLP-1 receptor agonists may treat fatty liver disease through dual action: directly reducing liver fat and inflammation while potentially improving gut microbiome balance.
Dual mechanism proposedGLP-1 drugs may benefit fatty liver through both direct liver effects and indirect gut-liver axis improvement
What the researchers found
GLP-1 receptor agonists may treat MAFLD through dual action on the gut-liver axis, reducing liver fat and inflammation while potentially improving gut microbiome balance.
Why it matters
Fatty liver disease affects about a quarter of the world's population and can progress to cirrhosis and liver cancer. Currently there are very few approved treatments, making GLP-1 drugs a promising option.
The numbers in context
MAFLD is described as one of the most common liver diseases worldwide with increasing prevalence. Advanced cases can progress to fibrosis, cirrhosis, and hepatocellular carcinoma.
How the study worked
Narrative review of the gut-liver axis in MAFLD pathogenesis and the role of GLP-1 receptor agonists in treatment.
Who was studied
Review covering patients with metabolic dysfunction-associated fatty liver disease
What this study cannot tell us
Narrative review without systematic methodology. Much of the gut microbiome evidence comes from animal studies.
How to read the evidence
Rated moderate: well-structured narrative review combining established liver effects with emerging gut microbiome evidence, though the latter is mostly preclinical.
When this study was published
Published in 2024. The gut-liver axis in MAFLD is a rapidly evolving research area.
The bigger picture
The gut-liver axis is increasingly recognized as central to liver disease. GLP-1 drugs that address both gut permeability and liver inflammation could provide a uniquely comprehensive treatment approach.
Questions still open
- Do GLP-1 drugs actually change the gut microbiome in humans?
- Could combining GLP-1 drugs with probiotics enhance liver benefits?
Common questions
Can GLP-1 drugs treat fatty liver disease?
What is the gut-liver axis?
Read the original research
Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease.
World journal of gastroenterology, 30(23), 2964-2980
Citation
Rochoń, Jakub; Kalinowski, Piotr; Szymanek-Majchrzak, Ksenia; Grąt, Michał. (2024). Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease.. World journal of gastroenterology, 30(23), 2964-2980. https://doi.org/10.3748/wjg.v30.i23.2964